Clinical Reports

March 02, 2022 | Download PDF

Drug Insights Q1-2022

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications.

Drug Insights Q1-2022

Clinical Reports Article

IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food and Drug Administration (FDA) approvals

Drug + Biologic Pipeline Q1-2022

Clinical Reports Article

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications.

Drug Insights Q4-2021

Clinical Reports Article

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming FDA approvals.

Drug + Biologic Pipeline Q4-2021

Clinical Reports Article

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming FDA approvals.

Drug + Biologic Pipeline Q3-2021

Clinical Reports Article

IngenioRx’s DrugInsights offers a quarterly summary of new molecular entities, formulations, and indications approved by the Food and Drug Administration (FDA).

Drug Insights Q3-2021

Clinical Reports Article

IngenioRx’s DrugInsights offers a quarterly summary of new molecular entities, formulations, and indications approved by the Food and Drug Administration (FDA).

Drug Insights Q2-2021

Clinical Reports Article

The Q2 2021 IngenioRx Drug and Biologic Pipeline Update highlights several emerging therapies in the pharmaceutical pipeline

Drug + Biologic Pipeline Q2-2021

Clinical Reports Article

IngenioRx closely monitors drugs, biologics, and gene therapies in development. Our Q1 2021 IngenioRx Drug and Biologic Pipeline Update highlights significant upcoming FDA approvals.

Drug + Biologic Pipeline Q1-2021

Clinical Reports Article

Introducing DrugInsights, a brand-new clinical publication from IngenioRx. This quarterly newsletter will highlight the latest FDA approvals to arrive on the market.

Drug Insights Q1-2021

Clinical Reports Article

This part of our 2020 Drug Trend report highlights our ability to drive savings across both medical and pharmacy benefits. Download it here to learn more.

Drug Trend Report 2020 - Total View

Clinical Reports Article

Despite global challenges, 2020 allowed us to step back and take a critical look at the needs of our sponsors and members

Drug Trend Report 2020 - Specialty Supplement

Clinical Reports Article

This third part of our 2020 Drug Trend Report celebrates the creative ways we truly put members at the center of everything we do

Drug Trend Report 2020 - Reimagining

Clinical Reports Article

Download our Q4 2020 IngenioRx Drug and Biologic Pipeline Update – an essential read for understanding how the drug and biologic pipeline could unfold in the coming months.

Drug + Biologic Pipeline Q4-2020

Clinical Reports Article

Our new quarterly Drug and Biologic Pipeline Update provides an overview of emerging new therapies, including in-depth analysis of newly approved drugs

Drug + Biologic Pipeline Q3-2020

Clinical Reports Article

2019 was notable, as we successfully transitioned our clients and their millions of members to IngenioRx.

Drug Trend Report 2019 - Relentless Pursuit

Stay up to date with the latest from IngenioRx